Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Overview
Supernus Pharmaceuticals Inc. is a specialty biopharmaceutical company with more than two decades of experience in pioneering new medicines in the fields of neurology and psychiatry. The company is dedicated to developing and commercializing innovative treatments for a wide range of central nervous system (CNS) disorders. With a robust neuroscience portfolio and a focus on both neurological and psychiatric conditions, Supernus leverages its proprietary and in-licensed technologies to optimize the therapeutic benefit of known drug compounds. This approach not only reduces development risks, costs, and time but also positions the company as a trusted contributor to the evolving landscape of CNS therapeutics.
Core Business and Scientific Expertise
At its core, Supernus Pharmaceuticals focuses on the research, development, and commercialization of treatments targeting CNS disorders. The company has established a significant presence in both neurology and psychiatry through its diverse portfolio of products. Utilizing a blend of innovative research and well-established drug mechanisms, Supernus develops therapies that address conditions such as epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), and various movement disorders associated with Parkinson's disease. The company’s emphasis on repurposing known compounds through novel formulations highlights its commitment to scientific rigor and operational efficiency.
Product Portfolio and Therapeutic Areas
Supernus has carved out a unique niche in the specialty pharmaceutical market by focusing on therapies that address pressing unmet medical needs. The company has successfully launched novel formulations in the neurology space, including treatments that offer extended-release benefits, thereby improving patient adherence and outcomes. In psychiatry, its portfolio includes non-stimulant options for ADHD that provide an alternative treatment pathway, emphasizing safety and tolerability. Other approved therapies cover a broad spectrum of CNS indications such as dyskinesia and chronic symptoms in Parkinson’s disease, as well as conditions like migraine and epilepsy.
Research and Development Excellence
The R&D strategy at Supernus is built around a dual approach that exploits both proprietary and in-licensed technologies. This method enables the company to fast-track the development of new product candidates by exploring novel uses for known compounds. Through rigorous clinical studies and a commitment to robust scientific research, Supernus has established an impressive clinical trial pipeline that reinforces its role in developing reliable therapeutic solutions. The company’s expertise is reflected in its ability to design and execute clinical protocols that yield meaningful, measurable improvements in patient well-being, particularly in conditions that have historically been challenging to treat.
Innovation Through Collaboration
Collaboration is a key driver of Supernus Pharmaceuticals' success. The company has entered strategic partnerships that broaden its commercial reach and accelerate regulatory approval processes in various regions, including Latin America. By aligning with international partners who share a commitment to innovation and patient access, Supernus enhances its capability to transform regional treatment paradigms. These partnerships not only expand market access but also reinforce its dedication to providing alternative treatment options for complex CNS conditions such as ADHD and depression.
Operational Model and Market Significance
Supernus’ operational framework emphasizes efficiency and risk mitigation. The company’s strategy of focusing on known drug compounds with established safety profiles allows for streamlined clinical development and regulatory review. This operational model ensures that the company can consistently bring high-quality therapies to market while effectively managing development risks. Investors and healthcare professionals recognize Supernus for its methodical approach, which combines scientific innovation with a deep understanding of the CNS therapeutic landscape.
Industry Position and Competitive Landscape
Positioned within a highly competitive specialty pharmaceutical sector, Supernus Pharmaceuticals distinguishes itself by its extensive experience and a broad portfolio of CNS treatments. Rather than solely competing on product launch speed, the company emphasizes delivering measurable improvements in patient outcomes through rigorous clinical validation and innovative drug formulation. Its collaboration with leading regulatory bodies and strategic international partners further bolsters its reputation as a scientifically grounded and commercially savvy enterprise.
Transparency and Trustworthiness
The company’s commitment to transparency and scientific integrity is evident through its detailed clinical studies and clear communication regarding product safety and efficacy. Every facet of Supernus' reporting and product development adheres closely to industry best practices, ensuring that healthcare practitioners, investors, and patients can have confidence in the data and the therapeutic potential of its products.
Conclusion
Supernus Pharmaceuticals Inc. is an established player in the field of CNS therapeutics, harmoniously blending experienced research teams with strategic product development initiatives. Its comprehensive approach to treating complex neurological and psychiatric disorders, coupled with a strong commitment to innovation and patient-centric healthcare, positions it as a pivotal force within the specialty pharmaceutical industry. The company continues to redefine the boundaries of CNS treatment through targeted collaboration, advanced scientific research, and a commitment to operational excellence.
- Key Strengths: Proven expertise in CNS disorders, innovative R&D practices, strategic regulatory and commercial partnerships.
- Therapeutic Focus: Broad portfolio addressing epilepsy, migraine, ADHD, dyskinesia, and other related conditions.
- Operational Efficiency: Emphasis on optimizing known drug compounds to reduce clinical development risk.
- Collaborative Network: Active partnerships in international markets enhancing regional access and treatment options.
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in upcoming March investor conferences. Jack Khattar, President and CEO, will represent the company at these events.
The company will feature a fireside chat at the Barclays Global Healthcare Conference, which will be available via live audio webcast. Investors can access the webcast through the Events & Presentations section of Supernus's website at www.supernus.com. The webcast recording will remain accessible for 60 days following the conference.
Interested investors seeking meetings with Supernus management during these conferences should reach out to the respective conference coordinators for arrangements.
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in the TD Cowen 45th Annual Health Care Conference.
President and CEO Jack A. Khattar will engage in a fireside chat on March 3, 2025, at 11:10 a.m. ET in Boston, Mass. Interested investors can arrange meetings with management through the conference coordinator.
The presentation will be accessible via live audio webcast through the company's website investor relations section, with a replay available for 60 days post-conference.
Supernus Pharmaceuticals (SUPN) reported strong financial results for Q4 and full year 2024, with total revenues increasing 9% to $661.8 million. Qelbree showed exceptional growth with Q4 net sales up 60% to $74.4 million and full-year sales up 72% to $241.3 million. GOCOVRI sales also improved, rising 15% in Q4 to $36.9 million.
The company achieved full-year 2024 operating earnings of $81.7 million, compared to a loss in 2023. Notable developments include FDA approval of ONAPGO for Parkinson's disease, planned for launch in Q2 2025, and a patent extension for Qelbree until 2035.
For 2025, Supernus projects total revenues between $600-630 million and adjusted operating earnings of $105-130 million. The company maintains a strong financial position with $453.6 million in cash and marketable securities as of December 31, 2024.
Supernus Pharmaceuticals (SUPN) announced that its Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD) failed to meet its primary endpoint. The study did not show statistically significant improvement in depressive symptoms compared to placebo, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.
The trial results showed minimal difference between SPN-820 (LS mean ± Standard Error: -12.3 ± 0.96) and placebo (-11.9 ± 0.96), with no statistical significance. Secondary endpoints also showed no treatment difference. However, the drug demonstrated a favorable safety profile with few adverse events, consistent with previous clinical trials.
Supernus Pharmaceuticals (SUPN) has announced it will release its fourth quarter and full year 2024 financial results after market close on Tuesday, February 25, 2025. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring CEO Jack Khattar and CFO Tim Dec, who will present the results and host a Q&A session.
Investors can access the live webcast through the Events & Presentations section of Supernus's Investor Relations website. Pre-registration is available for participants who wish to join via phone. A replay of the call will be available on the company's website for 60 days following the live presentation.
Supernus Pharmaceuticals (SUPN) has received FDA approval for ONAPGO (apomorphine hydrochloride), the first and only subcutaneous apomorphine infusion device for treating motor fluctuations in adults with advanced Parkinson's disease. The device will be available in the U.S. in Q2 2025.
The approval is based on a Phase 3, 12-week study (N=107) that demonstrated significant reduction in daily OFF time and increase in GOOD ON time. ONAPGO provides continuous treatment during waking hours through a wearable subcutaneous infusion device, offering more consistent control without requiring invasive surgery.
The treatment has a 30-year history in Europe, where it has helped thousands of patients. Supernus will launch ONAPGO with comprehensive support, including a nurse education program and access support.
Supernus Pharmaceuticals (SUPN) announced FDA approval for an updated label of its ADHD treatment Qelbree. The update includes new pharmacodynamic data detailing serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition, highlighting the drug's multimodal pharmacodynamics.
The label update also includes new lactation data showing low transfer of Qelbree into breastmilk, making it the first ADHD treatment to meet post-marketing requirements following the 2019 FDA guidance on Clinical Lactation Studies. The study, involving 15 healthy lactating women, demonstrated that the relative infant dose was approximately 1% of the maternal daily dose.
Qelbree is approved for ADHD treatment in patients 6 years and older. The medication carries important safety information, including risks of increased suicidal thoughts and actions, blood pressure elevation, and heart rate changes.
Supernus Pharmaceuticals (Nasdaq: SUPN), a CNS-focused biopharmaceutical company, announced its participation in the 36th Annual Piper Sandler Healthcare Conference. President and CEO Jack A. Khattar will engage in a fireside chat on December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace.
The presentation will be accessible via live audio webcast through the company's website investor relations section, with a replay available for 60 days post-conference. Investors seeking meetings with management should contact the conference coordinator.
Supernus Pharmaceuticals (Nasdaq: SUPN) has announced its participation in the 2024 Jefferies London Healthcare Conference. President and CEO Jack Khattar will engage in a fireside chat on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London.
The event will be accessible via live audio webcast through the company's website investor relations section. Interested investors can arrange meetings with management through the Jefferies conference coordinator. A replay of the webcast will remain available for 60 days following the conference on the company's website.
Supernus Pharmaceuticals reported strong Q3 2024 financial results with total revenues of $175.7 million, up 14% year-over-year. Qelbree sales increased 68% to $62.4 million, while GOCOVRI sales grew 8% to $35.6 million. Operating earnings reached $40.9 million, compared to $8.1 million in Q3 2023. The company raised its full-year 2024 guidance, now expecting total revenues of $630-$650 million and operating earnings of $50-$65 million. Key pipeline developments include positive Phase 2a results for SPN-820 in major depressive disorder and progress in SPN-817's development for epilepsy.
FAQ
What is the current stock price of Supernus Pharma (SUPN)?
What is the market cap of Supernus Pharma (SUPN)?
What is the core focus of Supernus Pharmaceuticals?
Which therapeutic areas does Supernus address?
How does Supernus differentiate its product development approach?
What makes Supernus Pharmaceuticals an experienced player in the market?
How does the company ensure the safety and efficacy of its treatments?
What role do partnerships play in Supernus' business model?
How does Supernus approach clinical research?
Why is Supernus considered a trusted source in CNS therapeutics?
